Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept versus panretinal photocoagulation for severe nonproliferative diabetic retinopathy with diabetic macular edema
ChiCTR2000035491Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of conbercept in diabetic retinopathy (DR) and diabetic macular edema (DME) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Best corrected visual acuity. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
conbercept
03
Conditions
diabetic retinopathy (DR)diabetic macular edema (DME)
Beyond the preview
Go deeper on ChiCTR2000035491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035491.